Tilt Holdings and Smoore Technology Sign Debt and Security Agreement

Business by 2FIRSTS.ai
Feb.02.2024
Tilt Holdings and Smoore Technology Sign Debt and Security Agreement
Arizona-based cannabis vaporizer company Tilt Holdings has signed a debt and security agreement with Smoore International, expanding its credit limit.

In a report by mjbizdaily on February 1, it was disclosed that Tilt Holdings, a cannabis vaporizer company based in Arizona, has entered into a debt and security agreement with Smoore Technology (Smoore International), expanding its credit limit with Smoore Technology. The agreement came into effect on January 28th.

 

According to a news release, Smoore will be selling and delivering CCell vaping hardware products to Tilt's subsidiary, Jupiter Research, on credit under an agreement. Jupiter will ensure payment for any amount exceeding what Smoore receives through insurance, to cover outstanding invoices that are overdue by more than 120 days.

 

The insurance will be provided by Sinosure, the China Export & Credit Insurance Corporation. This guarantee allows Tilt to increase and secure its credit limit to meet customer demands. Smoore will have the first priority lien on Tilt's assets.

 

In addition, Tilt has also agreed in a written agreement to reduce its outstanding balance owed to Smoore to $25 million by the end of 2024. They have committed to prioritize payment for invoices that are overdue by 150 days, followed by invoices that are overdue by 120 days.

 

Tim Conder, CEO of Tilt, stated in a press release, "We believe that reaching an agreement with Smoore is an important and necessary step in expanding our business and meeting customer demands. As the Chinese New Year holiday approaches, we have also successfully fulfilled the largest batch of CCELL product orders in Jupiter's history."

 

Tim Conder also stated that Tilt has engaged in discussions with bondholders regarding a grace period agreement. Throughout the process, the bondholders have shown unwavering support for Tilt and are hopeful to achieve mutual maximum benefits with the company.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary's government announced on November 18, 2026, plans to terminate the exclusive tobacco retail supply concession held by Országos Dohányboltellátó (ODBE) on June 1, 2027, approximately eight years before the contract's scheduled expiry in 2035. ODBE is owned 49% by a Hungarian subsidiary of British American Tobacco (BAT) and 51% by Tabán Trafik. It has served as the exclusive supplier to Hungary's licensed tobacco retail network since 2015. The proposed legislation would end the concession without compensation and allow other qualified suppliers and tobacco wholesalers to serve retailers directly. ODBE generated HUF 67.3 billion (approximately $200 million) in after-tax profit between 2015 and 2025 and distributed nearly HUF 64 billion ($191 million) in dividends. The bill also proposes changes to retail margins, inventory rules, payment arrangements and procurement penalties, including those affecting heated tobacco products.
company
Nov.19 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma passed a government-sponsored amendment on November 11, 2026, by 414 votes to none, seeking to prevent businesses from classifying information on the presence and number of types of certain harmful ingredients in tobacco and nicotine-containing products as trade secrets. The measure covers ingredients capable of increasing nicotine dependence or exhibiting toxic, carcinogenic, mutagenic or reproductive toxicity, including substances that acquire such properties during heating or smoldering. Bill No. 1286415-8 would amend Article 5 of Federal Law No. 98-FZ on Commercial Secrets and is scheduled to take effect on January 1, 2027. The bill has cleared all three readings in the State Duma but has not completed the remaining legislative procedures.
Regulations
Nov.12 by 2Firsts Perspectives
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20